About the Study
Chikungunya is an illness caused by a virus that spreads through mosquito bites, similar to other mosquito spread illnesses like Zika, Malaria, Dengue and West Nile Virus. Currently, there is no vaccine to prevent or medicine to treat Chikungunya virus infection.
Although Chikungunya is more prevalent in countries such as Latin America, Africa, Asia, Europe and the Indian and Pacific Oceans, there is an increasing risk infected mosquitos will be brought to new areas by travelers. In 2015 there was a major Chikungunya outbreak that affected several countries including regions of the Americas like Florida, Puerto Rico and the US Virgin Islands.
Rochester Clinical Research is seeking volunteers to participate in a study evaluating the immune response to a single dose Chikungunya vaccine in generally healthy adults to demonstrate manufacturing consistency. The study will be able to measure the antibodies in your blood to see if you are protected against the Chikungunya virus and that manufacturing of the vaccine is effective across manufacturing lots. This vaccine hopefully will be made and distributed to those living in affected areas or those who travel to Chikungunya infected areas. There is a zero chance of receiving placebo in this study. As a participant you will receive the vaccine from 1 of 3 manufacturing lots. This study lasts approximately 8 months with 6 visits to our office. Compensation up to $660 is available for those who qualify.
- Between 18-45 years old
- No history of treatment for Chikungunya or vaccination against it.
- No severe allergy history to vaccinations
- Please note, other conditions may apply